Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Noven Files Patent Suit Against Watson Over Daytrana Copy

Hisamitsu Pharmaceutical Co.’s Noven Pharmaceuticals unit sued Watson Pharmaceuticals Inc. to prevent it from selling a generic version of Daytrana, a skin patch for children with attention deficit disorder.

Watson is seeking U.S. Food and Drug Administration approval to sell a copy of Daytrana, according to the complaint filed today in federal court in Newark, New Jersey. Miami-based Noven said the Watson version would infringe two patents and seeks a court order to prevent sales until the patents expire in 2018.

Under federal drug law, the filing of the lawsuit prevents the FDA from granting Watson final approval for 30 months unless a court rules in the generic-drug maker’s favor before then.

“We are challenging the patents on the product,” said Charlie Mayr, a spokesman for Parsippany, New Jersey-based Watson, in a phone interview. He declined to comment further.

The case is Noven Pharmaceuticals v. Watson Laboratories, U.S. District Court, District of New Jersey (Newark).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.